Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMLX NASDAQ:CNTA NASDAQ:PTCT NASDAQ:RYTM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMLXAmylyx Pharmaceuticals$13.55+4.2%$15.14$4.80▼$18.60$1.45B-0.161.09 million shs999,020 shsCNTACentessa Pharmaceuticals$39.76+0.2%$39.40$11.77▼$40.26$5.92B1.111.11 million shs2.30 million shsPTCTPTC Therapeutics$73.68+4.0%$70.13$43.17▼$87.50$5.88B0.561.03 million shs1.87 million shsRYTMRhythm Pharmaceuticals$87.86+2.2%$87.77$60.70▼$122.20$5.89B1.91542,641 shs626,442 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMLXAmylyx Pharmaceuticals+4.15%+1.96%-8.01%-9.24%+149.08%CNTACentessa Pharmaceuticals+0.15%-0.35%+0.43%+40.89%+233.00%PTCTPTC Therapeutics+3.97%+7.99%-0.01%+12.20%+42.54%RYTMRhythm Pharmaceuticals+2.25%+4.16%-6.70%-2.40%+31.68%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMLXAmylyx Pharmaceuticals$13.55+4.2%$15.14$4.80▼$18.60$1.45B-0.161.09 million shs999,020 shsCNTACentessa Pharmaceuticals$39.76+0.2%$39.40$11.77▼$40.26$5.92B1.111.11 million shs2.30 million shsPTCTPTC Therapeutics$73.68+4.0%$70.13$43.17▼$87.50$5.88B0.561.03 million shs1.87 million shsRYTMRhythm Pharmaceuticals$87.86+2.2%$87.77$60.70▼$122.20$5.89B1.91542,641 shs626,442 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMLXAmylyx Pharmaceuticals+4.15%+1.96%-8.01%-9.24%+149.08%CNTACentessa Pharmaceuticals+0.15%-0.35%+0.43%+40.89%+233.00%PTCTPTC Therapeutics+3.97%+7.99%-0.01%+12.20%+42.54%RYTMRhythm Pharmaceuticals+2.25%+4.16%-6.70%-2.40%+31.68%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMLXAmylyx Pharmaceuticals 2.75Moderate Buy$23.0069.74% UpsideCNTACentessa Pharmaceuticals 2.21Hold$41.333.96% UpsidePTCTPTC Therapeutics 2.71Moderate Buy$91.3623.99% UpsideRYTMRhythm Pharmaceuticals 2.83Moderate Buy$131.8150.03% UpsideCurrent Analyst Ratings BreakdownLatest AMLX, RYTM, CNTA, and PTCT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/9/2026PTCTPTC Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$75.00 ➝ $108.006/8/2026AMLXAmylyx Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$34.006/3/2026RYTMRhythm Pharmaceuticals CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform5/27/2026PTCTPTC Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy$76.00 ➝ $85.005/11/2026PTCTPTC Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D)5/8/2026AMLXAmylyx Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)5/8/2026PTCTPTC Therapeutics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$94.005/8/2026PTCTPTC Therapeutics TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy$75.00 ➝ $90.005/8/2026PTCTPTC Therapeutics Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSector Perform$81.00 ➝ $82.005/8/2026PTCTPTC Therapeutics Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$86.00 ➝ $95.005/7/2026RYTMRhythm Pharmaceuticals Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$140.00 ➝ $143.00(Data available from 6/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMLXAmylyx Pharmaceuticals$87.37M17.24N/AN/A$2.78 per share4.87CNTACentessa Pharmaceuticals$15M395.56N/AN/A$3.92 per share10.14PTCTPTC Therapeutics$1.73B3.53$9.13 per share8.07($2.56) per share-28.78RYTMRhythm Pharmaceuticals$189.76M31.73N/AN/A$2.08 per share42.24Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMLXAmylyx Pharmaceuticals-$144.74M-$1.50N/AN/AN/AN/A-55.69%-50.73%8/6/2026 (Estimated)CNTACentessa Pharmaceuticals-$197.53M-$1.79N/AN/AN/AN/A-60.37%-44.17%8/11/2026 (Estimated)PTCTPTC Therapeutics$682.64M-$2.33N/A39.405.98-22.58%-362.45%-6.76%8/6/2026 (Estimated)RYTMRhythm Pharmaceuticals-$196.54M-$3.13N/AN/AN/A-93.33%-203.25%-44.99%8/4/2026 (Estimated)Latest AMLX, RYTM, CNTA, and PTCT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026AMLXAmylyx Pharmaceuticals-$0.34-$0.37-$0.03-$0.37N/AN/A5/7/2026Q1 2026PTCTPTC Therapeutics-$0.45-$0.03+$0.42-$0.03$217.42 million$272.55 million5/5/2026Q1 2026CNTACentessa Pharmaceuticals-$0.38-$0.52-$0.14-$0.52N/AN/A5/5/2026Q1 2026RYTMRhythm Pharmaceuticals-$0.86-$0.83+$0.03-$0.83$55.78 million$60.11 million3/31/2026Q4 2025CNTACentessa Pharmaceuticals-$0.38-$0.48-$0.10-$0.48$0.77 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAMLXAmylyx PharmaceuticalsN/AN/AN/AN/AN/ACNTACentessa PharmaceuticalsN/AN/AN/AN/AN/APTCTPTC TherapeuticsN/AN/AN/AN/AN/ARYTMRhythm PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMLXAmylyx PharmaceuticalsN/A17.8517.85CNTACentessa Pharmaceuticals0.239.539.53PTCTPTC TherapeuticsN/A2.442.36RYTMRhythm PharmaceuticalsN/A4.173.89Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMLXAmylyx Pharmaceuticals95.84%CNTACentessa Pharmaceuticals82.01%PTCTPTC TherapeuticsN/ARYTMRhythm PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipAMLXAmylyx Pharmaceuticals10.90%CNTACentessa Pharmaceuticals4.09%PTCTPTC Therapeutics5.50%RYTMRhythm Pharmaceuticals5.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMLXAmylyx Pharmaceuticals200111.19 million99.07 millionOptionableCNTACentessa Pharmaceuticals200149.23 million143.13 millionOptionablePTCTPTC Therapeutics1,41082.95 million78.39 millionOptionableRYTMRhythm Pharmaceuticals14068.53 million64.49 millionOptionableAMLX, RYTM, CNTA, and PTCT HeadlinesRecent News About These CompaniesRhythm Pharmaceuticals, Inc. (RYTM) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 8 at 6:00 PM | seekingalpha.comHow Investors May Respond To Rhythm Pharmaceuticals (RYTM) Updating Its Bardet-Biedl Diagnosis AlgorithmJune 8 at 2:46 PM | finance.yahoo.comRhythm Pharmaceuticals: The Rare Obesity Platform Is Becoming A Commercial EngineJune 3, 2026 | seekingalpha.comZweig DiMenna Associates LLC Buys New Shares in Rhythm Pharmaceuticals, Inc. $RYTMMay 30, 2026 | marketbeat.comRhythm Pharmaceuticals Announces Seven Abstracts Accepted for Presentation at ENDO 2026May 29, 2026 | globenewswire.comRhythm Pharmaceuticals Announces Publication of New Bardet-Biedl Syndrome Diagnostic Algorithm in the American Journal of Medical GeneticsMay 28, 2026 | globenewswire.comRhythm Pharmaceuticals Announces Participation in Upcoming Investor ConferencesMay 26, 2026 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Rhythm Pharmaceuticals (RYTM) and Cardiff Oncology (CRDF)May 22, 2026 | theglobeandmail.comRhythm Pharmaceuticals, Inc. (RYTM) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 13, 2026 | seekingalpha.comHC Wainwright Issues Pessimistic Outlook for RYTM EarningsMay 13, 2026 | marketbeat.comComerica Bank Cuts Stake in Rhythm Pharmaceuticals, Inc. $RYTMMay 13, 2026 | marketbeat.comRhythm Pharmaceuticals Announces New Data Presentations at the 2026 European Congress of EndocrinologyMay 12, 2026 | markets.businessinsider.comRhythm Pharmaceuticals Announces New Data Presentations at the 2026 European Congress of EndocrinologyMay 12, 2026 | globenewswire.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This YearMay 8, 2026 | finance.yahoo.comRhythm Pharmaceuticals, Inc. 2026 Q1 - Results - Earnings Call PresentationMay 7, 2026 | seekingalpha.comRhythm Pharmaceuticals Announces Participation in Upcoming Bank of America Global Healthcare ConferenceMay 6, 2026 | globenewswire.comRhythm Pharmaceuticals Weighs Long Term IMCIVREE Data And Growth PotentialMay 5, 2026 | finance.yahoo.comRhythm Pharmaceuticals, Inc. (RYTM) Q1 2026 Earnings Call TranscriptMay 5, 2026 | seekingalpha.comRhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Tops Revenue EstimatesMay 5, 2026 | zacks.comRhythm Pharmaceuticals Reports First Quarter 2026 Financial Results and Business UpdateMay 5, 2026 | globenewswire.comHow The Rhythm Pharmaceuticals (RYTM) Narrative Is Shifting On EMANATE Results And IMCIVREE ExpansionMay 4, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 20265 Stocks Winning the AI Race While Everyone Watches NVIDIABy Bridget Bennett | May 26, 2026The Smart Glasses Gold Rush Is Leaving Old-School Eyewear BehindBy Jeffrey Neal Johnson | May 24, 2026Before the Moon Base Gets Built, These 4 Companies WinBy Thomas Hughes | May 11, 2026Amylyx Stock: Why the Full Pipeline Story MattersBy Chris Markoch | May 24, 2026AMLX, RYTM, CNTA, and PTCT Company DescriptionsAmylyx Pharmaceuticals NASDAQ:AMLX$13.55 +0.54 (+4.15%) Closing price 06/9/2026 04:00 PM EasternExtended Trading$13.59 +0.04 (+0.32%) As of 06:29 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.Centessa Pharmaceuticals NASDAQ:CNTA$39.76 +0.06 (+0.15%) Closing price 06/9/2026 04:00 PM EasternExtended Trading$39.76 0.00 (0.00%) As of 06/9/2026 05:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.PTC Therapeutics NASDAQ:PTCT$73.68 +2.81 (+3.97%) Closing price 06/9/2026 04:00 PM EasternExtended Trading$73.72 +0.04 (+0.05%) As of 06:33 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.Rhythm Pharmaceuticals NASDAQ:RYTM$87.86 +1.93 (+2.25%) Closing price 06/9/2026 04:00 PM EasternExtended Trading$88.07 +0.21 (+0.24%) As of 06:14 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Corning Is Paving AI's Future With Glass The J.M. Smucker Company’s Dividend: Too Sweet to Ignore? Why's Amazon Suddenly Lagging the S&P 500, and Is It a Warning? Apple's Siri AI Was Finally Announced, So Why Is the Stock Tanking? From Crypto to AI: Insiders Are Trading These 3 Stocks The Case for Intel Over Pure-Play Quantum Firms Has Temu-Owner PDD's Story Changed After Double Miss? Campbell's Soup Stock: Deep Value and a 7% Dividend Yield Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
